#USA #Indianapolis #Carnyx Therapeutics #CNYX-005 #NREM sleep

Carnyx Therapeutics Unveils Innovative Sleep Therapy CNYX-005

Carnyx Therapeutics, a biopharmaceutical company in the preclinical stage, recently revealed its leading oral sleep treatment candidate, CNYX-005. This new drug aims to address sleep disorders and specifically targets the enhancement of non-rapid eye movement (NREM) sleep. The disclosed preclinical research reveals that CNYX-005 can increase total sleep duration by approximately 1.5 to 2 hours in aged rat models, primarily through extending the time spent in NREM sleep, a stage essential for restorative processes in the body.

The study captured sleep patterns using continuous electroencephalography (EEG), enabling investigators to analyze sleep architecture in detail. According to Carnyx CEO, Professor Patrick Gunning, the objective extends beyond merely inducing sleep; they aim to facilitate a more restorative sleep experience. The increase in NREM sleep observed is intriguing, suggesting that CNYX-005 has the potential to positively influence the overall quality of sleep rather than just the quantity.

NREM sleep plays a critical role in various restorative physiological functions, including growth, hormone secretion, and tissue repair. Unfortunately, as age progresses, NREM sleep duration typically diminishes, leading to increased fragmentation and reduced quality of sleep.

In an exciting development for the company, Dr. Chris Brearley has joined Carnyx as Chief Medical Officer. Dr. Brearley brings with him over three decades of expertise in translational medicine and drug development, having held significant positions at major pharmaceutical companies like Pfizer and Amgen. His extensive background encompasses the design and management of early-stage clinical trials, which will be vital as Carnyx moves CNYX-005 into clinical development.

Dr. Brearley remarked on the promising findings from the preclinical data, emphasizing their importance for advancing CNYX-005's development. He expressed anticipation for translating these insights into a systematic clinical program aiming to evaluate the medication's restorative effects on sleep.

CNYX-005 stems from the company’s extensive research into the biology of peptides related to sleep regulation and healthy aging. The compound is being developed using innovative approaches in medicinal chemistry and pharmacology. Carnyx aims to systematically study the efficacy, safety, and pharmacokinetics of CNYX-005 as they progress towards clinical trials.

Recent attention has also been drawn to peptides in the healthcare industry, particularly as the U.S. Food and Drug Administration (FDA) has begun reviewing certain peptides for potential use in pharmaceutical compounding. Professor Gunning noted the increasing scientific and public curiosity surrounding peptides, recognizing the need for rigorous clinical validation. Carnyx's focus remains steadfast on transforming promising biological findings into viable therapeutic candidates through methodical preclinical and clinical assessments.

Aside from CNYX-005, the firm is also developing another investigational drug, CNYX-001, aimed at treating retinitis pigmentosa, showcasing their commitment to addressing unmet medical needs in diverse areas of health.

In summary, Carnyx Therapeutics is leading the charge in developing innovative solutions for sleep disorders through their candidate drug CNYX-005. As the company moves forward, it is poised to redefine sleep treatment paradigms with a focus on improving sleep quality and restorative functions, promising a brighter tomorrow for those affected by sleep inadequacies.